The Role of Circulating Tumor Cells in Chemoresistant Metastatic Breast Cancer.
Lorena Alexandra LisencuEduard Alexandru BonciAlexandru IrimieOvidiu BalacescuCosmin LisencuPublished in: Journal of clinical medicine (2021)
Breast cancer is the most frequent form of cancer among women and is one of the leading causes of death. Two routes of the metastatic process have been described: linear and parallel progression. A key factor is represented by circulating tumor cells (CTCs). CTCs detach from the primary tumor or develop from cancer stem cells (CSCs) that undergo epithelial-to-mesenchymal transition (EMT). CTCs migrate to the distant site where the reverse process occurs and a new tumor arises. One of the key problems of metastatic disease is chemoresistance, which leads to treatment failure and, eventually, death. The aim of this review is to present up-to-date data regarding the role of CTCs in chemoresistance in metastatic breast cancer (MBC) patients. A search in Cochrane Library and MEDLINE databases was performed. A total of 125 articles were identified. The results of the final 12 eligible studies revealed that CTCs having stem cell features and those with mesenchymal features are aggressive subtypes of cells that survive chemotherapy, being responsible for chemoresistance and thus for disease progression in MBC patients. The hemodynamic shear stress, alongside dynamic changes among CTCs during the disease, is also an important disease progression factor.
Keyphrases
- circulating tumor cells
- metastatic breast cancer
- cancer stem cells
- end stage renal disease
- stem cells
- circulating tumor
- chronic kidney disease
- ejection fraction
- prognostic factors
- squamous cell carcinoma
- peritoneal dialysis
- big data
- induced apoptosis
- mental health
- bone marrow
- adipose tissue
- lymph node
- polycystic ovary syndrome
- oxidative stress
- cell death
- mesenchymal stem cells
- skeletal muscle
- deep learning
- insulin resistance
- young adults
- single cell
- artificial intelligence
- metabolic syndrome
- radiation therapy
- lymph node metastasis
- cell free